• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying

    12/26/23 6:49:08 AM ET
    $ATXS
    $IHT
    $STCN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $ATXS alert in real time by email

    Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    InnSuites Hospitality Trust

    • The Trade: InnSuites Hospitality Trust (NYSE:IHT) President and CEO James F Wirth acquired a total of 2,000 shares an average price of $2,809.35. To acquire these shares, it cost around $5.62 million.
    • What’s Happening: InnSuites Hospitality recently reported an increase in quarterly sales.
    • What InnSuites Hospitality Trust Does: InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties.

    Astria Therapeutics

    • The Trade: Astria Therapeutics, Inc. (NASDAQ:ATXS) Director Joseph Edelman acquired a total of 740,000 shares at an average price of $6.20. To acquire these shares, it cost around $4.59 million.
    • What’s Happening: Astria Therapeutics, last month, posted a narrower quarterly loss.
    • What Astria Therapeutics Does: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases.

    Don’t forget to check out our premarket coverage here

    Steel Connect

    • The Trade: Steel Connect, Inc. (NASDAQ:STCN) 10% owner WF Asset Corp. bought a total of 9,437 shares at an average price of $9.60. To acquire these shares, it cost around $90,628.
    • What’s Happening: Steel Connect recently reported a decline in quarterly sales.
    • What Steel Connect Does: Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain.

     

    Check This Out: Top 5 Industrials Stocks That Are Ticking Portfolio Bombs

    Get the next $ATXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXS
    $IHT
    $STCN

    CompanyDatePrice TargetRatingAnalyst
    Astria Therapeutics Inc.
    $ATXS
    11/12/2025Overweight → Neutral
    Cantor Fitzgerald
    Astria Therapeutics Inc.
    $ATXS
    9/17/2025$16.00 → $20.00Buy
    H.C. Wainwright
    Astria Therapeutics Inc.
    $ATXS
    4/29/2025$47.00Overweight
    Cantor Fitzgerald
    Astria Therapeutics Inc.
    $ATXS
    1/31/2025$26.00Mkt Outperform
    JMP Securities
    Astria Therapeutics Inc.
    $ATXS
    7/29/2024$35.00Buy
    TD Cowen
    Astria Therapeutics Inc.
    $ATXS
    3/28/2023$18.00Outperform
    Evercore ISI
    Astria Therapeutics Inc.
    $ATXS
    9/29/2021$20.00Buy
    Jefferies
    More analyst ratings

    $ATXS
    $IHT
    $STCN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.

    SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    2/12/26 4:58:09 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by InnSuites Hospitality Trust Shares of Beneficial Interest

    144 - INNSUITES HOSPITALITY TRUST (0000082473) (Subject)

    2/12/26 11:10:02 AM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SCHEDULE 13D/A filed by Astria Therapeutics Inc.

    SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    2/9/26 5:03:25 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    $IHT
    $STCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IHT ANNOUNCES BREAKTHROUGH IN UNIGEN DIVERSIFICATION PROJECT INVESTMENT

    Phoenix, AZ, Feb. 23, 2026 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) On December 16, 2019, InnSuites Hospitality Trust made a $1 Million diversification investment in UniGen Power, Inc. A major breakthrough has occurred in the UniGen Power Inc. quest to successfully raise the next round of financing focused on completing engineering previously reported at 61% complete. This new financing could soon allow UniGen to complete the first two 1000NT new innovation prototypes. On February 20, 2026, the recently reconstituted UniGen Board elected an all-new management team electing James Wirth (IHT President, CEO, and Chairman) to fill vacant UniGen positions as President, CEO, a

    2/23/26 6:25:00 AM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    IHT DECLARES 56TH CONSECUTIVE ANNUAL DIVIDEND AS HOTEL REVENUES SURGE

    Phoenix, AZ, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) On January 12, 2026, the Board of Trustees of InnSuites Hospitality Trust (NYSE Am: IHT), announced a semi-annual dividend of $0.01 per share payable on February 9, 2026, to shareholders of record as of January 27, 2026, extending an uninterrupted continuous 56-year history of annual dividends. InnSuites Hotel operations continue to remain strong, with a combined revenue total in December for the two hotels of $536,399. We are also pleased to report record revenues for the two hotels combined for the month of December 2025, and project record hotel total Revenues for our IHT hotels for the 2026 Fiscal Ye

    1/21/26 5:27:00 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Astria Stockholders Vote to Approve Acquisition by BioCryst

    Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger"). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. About Astria Therapeutics Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinica

    1/21/26 4:00:00 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    $IHT
    $STCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Wirth James F sold $82,991,377 worth of INNSUITES HOSPITALITY REIT (8,822 units at $9,407.32), decreasing direct ownership by 0.15% to 6,024,613 units (SEC Form 4)

    4 - INNSUITES HOSPITALITY TRUST (0000082473) (Issuer)

    3/2/26 6:25:08 AM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Director Violin Jonathan returned 263,321 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    1/23/26 4:37:09 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Morabito Christopher

    4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

    1/23/26 4:35:24 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    $IHT
    $STCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wirth James F bought $116,550 worth of INNSUITES HOSPITALITY REIT (300 units at $388.50), increasing direct ownership by 0.00% to 6,252,496 units (SEC Form 4)

    4 - INNSUITES HOSPITALITY TRUST (0000082473) (Issuer)

    5/31/24 4:25:12 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Wirth James F bought $52,808 worth of INNSUITES HOSPITALITY REIT (200 units at $264.04), increasing direct ownership by 0.00% to 6,252,196 units (SEC Form 4)

    4 - INNSUITES HOSPITALITY TRUST (0000082473) (Issuer)

    5/23/24 6:25:25 AM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    Wirth James F bought $211,584 worth of INNSUITES HOSPITALITY REIT (400 units at $528.96), increasing direct ownership by 0.01% to 6,251,996 units (SEC Form 4)

    4 - INNSUITES HOSPITALITY TRUST (0000082473) (Issuer)

    5/16/24 6:34:15 AM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    $ATXS
    $IHT
    $STCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Astria Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Astria Therapeutics from Overweight to Neutral

    11/12/25 12:18:19 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Astria Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00 from $16.00 previously

    9/17/25 11:36:24 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Astria Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00

    4/29/25 8:10:45 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    $IHT
    $STCN
    Financials

    Live finance-specific insights

    View All

    IHT DECLARES 56TH CONSECUTIVE ANNUAL DIVIDEND AS HOTEL REVENUES SURGE

    Phoenix, AZ, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) On January 12, 2026, the Board of Trustees of InnSuites Hospitality Trust (NYSE Am: IHT), announced a semi-annual dividend of $0.01 per share payable on February 9, 2026, to shareholders of record as of January 27, 2026, extending an uninterrupted continuous 56-year history of annual dividends. InnSuites Hotel operations continue to remain strong, with a combined revenue total in December for the two hotels of $536,399. We are also pleased to report record revenues for the two hotels combined for the month of December 2025, and project record hotel total Revenues for our IHT hotels for the 2026 Fiscal Ye

    1/21/26 5:27:00 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    IHT FISCAL FIRST THREE QUARTER HOTEL REVENUES EXCEED $5.8 MILLION; IBC DIVERSIFICATION GAINS MOMENTUM

    Phoenix, AZ, Dec. 15, 2025 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE:IHT) reported Hotel Revenue results surpassing $5.8 million once again in the First Three Fiscal Quarters of 2026, (February 1, 2025, to October 31, 2025), with Total Revenue of approximately $5,809,673. Consolidated Net Income before the non-cash expense of depreciation and the non-cash Best Western Rewards Guest Vouchers expense, was approximately break-even at (-48,000), for the 2026 First Fiscal Three Quarters ended October 31, 2025 (February 1, 2025, through October 31, 2025). IHT hotel operations were strong in the 2025 Fiscal Year ended January 31, 2025, and are contributing to a comparable 2026 Fisca

    12/15/25 5:29:00 PM ET
    $IHT
    Investment Bankers/Brokers/Service
    Finance

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ATXS
    $IHT
    $STCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:46:12 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

    SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 5:45:56 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Astria Therapeutics Inc.

    SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)

    11/14/24 4:41:28 PM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXS
    $IHT
    $STCN
    Leadership Updates

    Live Leadership Updates

    View All

    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

    Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl

    4/9/24 8:00:00 AM ET
    $ATXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Steel Connect, Inc. Amends Tax Benefits Preservation Plan

    SMYRNA, Tenn.--(BUSINESS WIRE)--Steel Connect, Inc. (the “Company”) (Nasdaq: STCN), today announced that its Board of Directors (the “Board”) amended its tax benefits preservation plan, dated as of January 19, 2018 (the “Plan”), to extend the term of the Plan to January 8, 2024 (subject to earlier expiration, as described below). The Company has significant net operating loss carryforwards for federal and state tax purposes and believes that its ability to utilize these net operating loss carryforwards and other tax attributes (collectively, “Tax Benefits”) would be substantially limited if the Company undergoes an “ownership change” (within the meaning of Section 382 of the Intern

    1/8/21 4:15:00 PM ET
    $STCN
    Business Services
    Consumer Discretionary